Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005)

A benchmark for emerging targeted cancer therapies

Authors

  • Arie S. Belldegrun MD,

    Corresponding author
    1. Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California
    • Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, 66-118 CHS, Box 951738, Los Angeles, CA 90095-1738===

    Search for more papers by this author
    • Fax: (310) 206-5343

  • Tobias Klatte MD,

    1. Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California
    Search for more papers by this author
  • Brian Shuch MD,

    1. Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California
    Search for more papers by this author
  • Jeffrey C. LaRochelle MD,

    1. Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California
    Search for more papers by this author
  • David C. Miller MD,

    1. Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California
    Search for more papers by this author
  • Jonathan W. Said MD,

    1. Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California
    2. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California
    Search for more papers by this author
  • Stephen B. Riggs MD,

    1. Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California
    Search for more papers by this author
  • Nazy Zomorodian MD,

    1. Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California
    Search for more papers by this author
  • Fairooz F. Kabbinavar MD,

    1. Department of Medicine, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California
    Search for more papers by this author
  • Jean B. deKernion MD,

    1. Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California
    Search for more papers by this author
  • Allan J. Pantuck MD

    1. Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California
    Search for more papers by this author

Abstract

BACKGROUND.

The management of renal cell carcinoma (RCC) is evolving toward less extirpative surgery and the use of targeted therapy. The authors set out to provide a benchmark against which emerging therapies should be measured.

METHODS.

A prospective database including clinical and pathological variables for 1632 patients with RCC treated between 1989 and 2005 was queried. Patients were stratified using the University of California-Los Angeles Integrated Staging System (UISS) into low-, intermediate-, and high-risk groups. Disease-specific survival (DSS) was measured. Response to systemic therapy for patients with advanced disease was assessed.

RESULTS.

Nephrectomy was performed in 1492 patients. Overall 5-, 10-, and 15-year DSS was 55%, 40%, and 29%. For localized disease, 5- and 10-year DSS for UISS low-, intermediate-, and high-risk groups was 97% and 92%, 81% and 61%, and 62% and 41%, respectively. For metastatic disease, 5- and 10-year DSS for UISS low-, intermediate-, and high-risk groups was 41% and 31%, 18% and 7%, and 8% and 0%, respectively. Patients with metastatic disease receiving immunotherapy (n = 453) had complete response in 7% (median survival [MS], 120+ months), partial response in 15% (MS, 42.8 months), stable disease in 33% (MS, 38.6 months), and progressive disease in 45% (MS, 11.6 months).

CONCLUSIONS.

Most patients with localized RCC do well with surgery alone, but effective adjuvant therapy is needed for patients identified as at high risk for recurrence. For advanced disease, newer targeted and potentially less toxic treatments should be at least as effective as those achieved with aggressive surgical resection and immunotherapy. Cancer 2008. © 2008 American Cancer Society.

Ancillary